Aim: Three weeks paclitaxel and carboplatin has been considered the standard of care for primary treatment of ovarian cancer (OC). Whether weekly therapy will further improve the clinical outcomes or not is still unclear. We conducted a meta-analysis to compare the two regimens. Method: Articles were selected with a systematic approach, using PubMed databases. Trials concerning comparison between carboplatin plus weekly paclitaxel (dose-dense regimen) and carboplatin plus paclitaxel every 3 weeks were considered. Outcomes included overall survival (OS), progression free survival (PFS) and severe acute toxicity. Results: Dose-dense regimen was associated with significant improvement of PFS compared with standard schedule, with HR of 0.73 (95% CI 0.61-0.88, p = 0.001). There was no difference in OS between treatment regimens (HR 0.95, 95% CI 0.77-1.16, p=0.06), as well as in term of severe acute toxicity. Conclusion: Dose-dense regimen is superior to standard schedule in terms of PFS. Further studies are necessary to firmly confirm this evidence in advanced OC treatment.
Weekly versus three weeks chemotherapy for advanced ovarian cancer: a meta-analysis / Marchetti, Claudia; De Felice, Francesca; Musella, Angela; Palaia, Innocenza; Monti, Marco; Musio, Daniela; Muzii, Ludovico; Tombolini, Vincenzo; Panici, Pierluigi Benedetti. - In: ONCOTARGET. - ISSN 1949-2553. - ELETTRONICO. - 7:36(2016), pp. 58709-58715. [10.18632/oncotarget.11094]
Weekly versus three weeks chemotherapy for advanced ovarian cancer: a meta-analysis
Marchetti, ClaudiaCo-primo
;De Felice, Francesca
Co-primo
;Musella, Angela;Palaia, Innocenza;Monti, Marco;Muzii, Ludovico;Tombolini, VincenzoPenultimo
;Panici, Pierluigi BenedettiUltimo
2016
Abstract
Aim: Three weeks paclitaxel and carboplatin has been considered the standard of care for primary treatment of ovarian cancer (OC). Whether weekly therapy will further improve the clinical outcomes or not is still unclear. We conducted a meta-analysis to compare the two regimens. Method: Articles were selected with a systematic approach, using PubMed databases. Trials concerning comparison between carboplatin plus weekly paclitaxel (dose-dense regimen) and carboplatin plus paclitaxel every 3 weeks were considered. Outcomes included overall survival (OS), progression free survival (PFS) and severe acute toxicity. Results: Dose-dense regimen was associated with significant improvement of PFS compared with standard schedule, with HR of 0.73 (95% CI 0.61-0.88, p = 0.001). There was no difference in OS between treatment regimens (HR 0.95, 95% CI 0.77-1.16, p=0.06), as well as in term of severe acute toxicity. Conclusion: Dose-dense regimen is superior to standard schedule in terms of PFS. Further studies are necessary to firmly confirm this evidence in advanced OC treatment.File | Dimensione | Formato | |
---|---|---|---|
Marchetti_Weekly_2017.pdf
accesso aperto
Note: https://www.oncotarget.com/article/11094/text/
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Creative commons
Dimensione
1.4 MB
Formato
Adobe PDF
|
1.4 MB | Adobe PDF | |
Weekly versus three weeks chemotherapy for advanced ovarian.pdf
solo utenti autorizzati
Tipologia:
Altro materiale allegato
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
1.88 MB
Formato
Adobe PDF
|
1.88 MB | Adobe PDF | Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.